Physician profile
Rachel Murthy
NPI 1104982115
$3,096.66
in general payments reported to CMS, 2019-2025
40 companies · $401 in 2025
The $401 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $396 · 2021: $441 · 2022: $489 · 2023: $499 · 2024: $436 · 2025: $401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,291 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.79 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $557.82 | 2019-2025 | |
| Astellas Pharma US INC | $394.08 | 2019-2025 | Veozah, Myrbetriq |
| Coopersurgical, INC. | $259.51 | 2021-2025 | Paragard T 380a, Paragard T 380a, Summit Doppler |
| Bayer Healthcare Pharmaceuticals INC. | $251.47 | 2019-2025 | |
| Daiichi Sankyo INC. | $179.19 | 2019-2022 | |
| Therapeuticsmd, INC. | $134.26 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $129.74 | 2021-2025 | |
| Pfizer INC. | $107.49 | 2021-2024 | |
| Organon LLC | $101.20 | 2021-2025 | Jada System |
| Sumitomo Pharma America, INC. | $99.46 | 2023-2025 | Myfembree |
| Amgen INC. | $77.19 | 2019-2021 | |
| Hologic Sales and Service, LLC | $71.60 | 2019-2025 | Aptima |
| Millicent US INC | $64.88 | 2024-2025 | Femring, Intrarosa |
| Duchesnay USA Incorporated | $61.37 | 2019 | |
| Biogen, INC. | $49.17 | 2024-2025 | Zurzuvae |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $44.85 | 2021 | |
| Merck Sharp & Dohme LLC | $38.91 | 2019-2021 | |
| Evofem Biosciences, INC. | $38.91 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $29.98 | 2020 | |
| Avion Pharmaceuticals | $28.19 | 2022 | |
| Agile Therapeutics, INC. | $26.76 | 2022 | |
| Innovation Technologies INC | $26.42 | 2025 | Irrisept |
| Radius Health, INC. | $25.61 | 2024 | Tymlos |
| Scynexis, INC. | $24.90 | 2022 | |
| Davol INC. | $23.71 | 2022 | |
| Viiv Healthcare Company | $23.66 | 2023 | Apretude |
| Ethicon US, LLC | $21.48 | 2020 | |
| Shield Therapeutics INC | $19.51 | 2023 | Accrufer |
| Pacira Pharmaceuticals Incorporated | $18.96 | 2020 | |
| Bard Access Systems, INC. | $18.71 | 2019 | |
| Lilly USA, LLC | $18.33 | 2025 | Zepbound |
| Roche Diagnostics Corporation | $18.26 | 2021 | |
| Amneal Pharmaceuticals LLC | $17.27 | 2022 | |
| Exact Sciences Corporation | $15.62 | 2023 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $14.75 | 2022 | |
| Allergan, INC. | $13.82 | 2019 | |
| Medtronic, INC. | $12.96 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.82 | 2023 | Quviviq |
| Minerva Surgical, INC | $12.58 | 2021 | |
| Lupin INC. | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Murthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.